Table 3 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit

Key Points

• Survival outcomes are affected by drug interactions in patients with solid tumors undergoing immunotherapy.
• The analysis highlights variables influencing treatment efficacy, emphasizing the need for tailored approaches.
• Assessment was performed using a phase I unit focusing on interactions between various therapeutic agents.
• Understanding these interactions may enhance patient management and improve treatment strategies in solid tumors.